EGFR and non-small cell lung carcinoma: The epidermal growth factor receptor (EGFR) [7] gene mutant state is critical for treatment plans, such as EGFR-tyrosine kinase inhibitor (EGFR-TKIs) administration, for NSCLC patients with BMs.